Opinion|Videos|April 10, 2025
Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
Panelists discuss how real-world analyses of chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory multiple myeloma (R/R MM), as presented in abstract #2408 by Amoozgar et al at ASH 2024, provide insights into the comparative efficacy and safety of ciltacabtagene autoleucel and idecabtagene vicleucel, highlighting differences between real-world outcomes and clinical trial results.
Advertisement
Episodes in this series
Video content above is prompted by the following:
CAR T-Cell Therapies in R/R Multiple Myeloma: Real-World Insights
Key Findings
- This retrospective intention-to-treat analysis compared the real-world efficacy and safety of 2 CAR T-cell therapies: ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) in R/R MM.
Comparative Performance
- Evaluated real-world outcomes to bridge the gap between controlled clinical trials and actual patient experiences
- Aimed to understand how these therapies perform in a more diverse, less controlled patient population
Potential Implications
- Provides critical insights into:
- Comparative effectiveness of 2 different CAR T-cell approaches
- Real-world safety profiles
- Practical considerations for treatment selection
- Patient outcomes outside of strict clinical trial protocols
Limitations and Considerations
- Retrospective study design
- Potential selection bias
- Need for further prospective validation
Clinical Relevance
- Helps physicians make more informed treatment decisions
- Offers a more nuanced understanding of CAR T-cell therapy performance in R/R MM
Advertisement
Related to this article
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC
5